Navigation Links
Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
Date:2/13/2008

pany is confident that it is making

progress toward fully resolving the production issues that emerged in

mid-2007. In addition, the FDA has accepted the company's responses

to the warning letter issued last year.

-- Total revenue for the Diagnostics/Genetics business is expected to

reach $475-$485 million this year, compared with $411 million in 2007.

The Genetics business has been experiencing particularly strong growth,

driven by an increasing demand for diagnostic testing services. Genzyme

is investing in additional information technology and infrastructure to

continue to strengthen the competitive advantages the Genetics unit has

created.

-- Sales of Aldurazyme are expected to increase to $135-$145 million this

year, compared with $123 million in 2007. Genzyme will record sales of

Aldurazyme and make tiered payments to BioMarin on worldwide product

sales. These payments will be recorded as a cost of goods sold.

Gross Margin

-- Genzyme's recognition of Aldurazyme revenue and the associated payments

to BioMarin will reduce the gross margin by approximately 1 percentage

point without any net impact on the bottom line. The non-GAAP gross

margin for 2008 is expected to be approximately 77 percent of revenue.

Expenses

-- Non-GAAP selling, general and administrative expenses are expected to

represent approximately 27 percent of revenue in 2008, consistent with

SG&A expenses in 2007. SG&A spending reflects the integration of

Bioenvision and the European rollout of Clolar, the ongoing

introduction of Myozyme, the sales force expansion associated with the

launch of Renvela, and the expanded U.S. sales effort for Sepra(R)

products.

-- Non-GAAP research and development spending is expected to represent

approximately 17 perce
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine news :

1. Genzyme Receives FDA Response Letter on Synvisc-One(TM)
2. Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
3. Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
4. Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS
5. Delaware Court Approves Bioenvision, Genzyme Joint Petition
6. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
7. Liquent Insight Publisher 3.6 Delivers Advanced Submission Capabilities
8. March of Dimes Delivers a New Look
9. Independence Blue Cross Delivers Important Reminder to Women during Cervical Cancer Awareness Month
10. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
11. Gleevec, the targeted cancer pill, delivers more good news to patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013 PhD Box ... the onset of the research process by offering assistance for ... to the repertoire of services that the company provides for ... behind launching a dedicated proposal writing service is that this ... new to the research process find it difficult to draft ...
(Date:5/23/2013)... Kitchen on Fire announces ... most advanced culinary technique series currently offered at this ... knowledge of how to purchase, butcher and cook the ... of organic, local ingredients. The new Intermediate Series consists ... each. The next series begins on Sunday, June 2, ...
(Date:5/23/2013)... Diego, CA (PRWEB) May 23, 2013 ... recently and they are now actively providing expert opinion ... Side Effects lawsuits. , According to court documents, ... in Illinois Southern District Court (case no. 3:2013cv50102) alleging ... Pradaxa, manufactured by Boehringer Ingelheim Pharmaceuticals, is mainly used ...
(Date:5/22/2013)... 2013 MileageAds.com, an American based full ... companies in the Stocks and Bonds Sector to display ... advertise with MileageAds will have the opportunity to take ... Stocks and bonds companies who accept Mileageads.com’s invitation will ... a specific, targeted audience on the internet ...
(Date:5/22/2013)... On May 16, 2012, LifeHealthPro reported that, ... concierge can help families negotiate lower costs for all aspects ... announces their top 3 reasons to hire a funeral ... U.S. having dropped 7.3 percent from $55,438 to $51,404 since ... 12.6% of an average U.S. households annual income. , Funeral ...
Breaking Medicine News(10 mins):Health News:PhD Box Unveils Proposal Writing Services for Research Scholars 2Health News:Kitchen on Fire Launches Intermediate Cooking Series, Advancing the Culinary Skills of Experienced Home Chefs 2Health News:Kitchen on Fire Launches Intermediate Cooking Series, Advancing the Culinary Skills of Experienced Home Chefs 3Health News:New Lawsuit on Pradaxa Brain Hemorrhage: Now, AttorneyOne Can Provide Advice 2Health News:Mileageads.com Ad Network Now Invites Companies in Stocks and Bonds Services Sector to Advertise on Their Ad Network 2Health News:Funeral Financials Announces Their Top 3 Reasons to Hire a Funeral Concierge 2Health News:Funeral Financials Announces Their Top 3 Reasons to Hire a Funeral Concierge 3
... , FRIDAY, Nov. 11 (HealthDay News) -- Certain types ... smokers who are generally anxious, according to a new study. ... to tune out anti-smoking videos that warn how smoking can ... harm others. "If you look at health messages, there ...
... Experts from The Neuroscience Institute at NYU Langone Medical ... discussions at the Society for Neuroscience 41st Annual Meeting ... meeting presents an opportunity for leading scientists from around ... for treating diseases and conditions of the brain," said ...
... Researchers at the University of Liverpool and the universities ... that cases of severe pneumonia among young children are ... cooking stoves. The research, published in the ... smoke from open fires and dirty cooking stoves, the ...
... scientists have developed a new technique using stem cells, ... disease. The technique could be developed for application in ... Thompson lead the research from the Florey Neuroscience Institutes ... the newly established Stem Cells Australia collaboration being launched ...
... THURSDAY, Nov. 10 (HealthDay News) -- Despite the known dangers ... but almost 70 percent want to quit, a new government ... Tim McAfee, director of the Office on Smoking and Health ... during a noon press conference Thursday. There was a ...
... (HealthDay News) -- Eating a high-fiber diet may reduce your ... cereal and whole grains, according to a new review. ... a total of nearly 2 million people. Compared with the ... increase in intake of total dietary fiber and cereal fiber ...
Cached Medicine News:Health News:Negative Anti-Smoking Ads Turn Off Anxious Viewers 2Health News:Woodsmoke from cooking fires linked to pneumonia 2Health News:Stem cell research hopes to repair brain damage of Parkinson's disease 2Health News:Stem cell research hopes to repair brain damage of Parkinson's disease 3Health News:Most Smokers Want to Quit, CDC Report Finds 2Health News:Most Smokers Want to Quit, CDC Report Finds 3Health News:Most Smokers Want to Quit, CDC Report Finds 4Health News:High-Fiber Diet May Help Thwart Colon Cancer 2
(Date:5/22/2013)... 22, 2013 Attorney Advertising -- Bronstein, Gewirtz ... behalf of purchasers of the securities of AMAG ... -News).  The investigation focuses on whether the Company ... On May 22, 2013, Shares of AMAG ... the company announced in regulatory filing that it ...
(Date:5/22/2013)... and MUNICH , May 22, 2013 /PRNewswire/ ... marketer of transcatheter aortic valve implantation (TAVI) systems for the ... results of the J enaValve Eval U ation of ... Pa T ients with S E vere Ao R tic ... . JUPITER is a post-market registry to evaluate five-year long ...
(Date:5/22/2013)... 22, 2013 The new 13-valent pneumococcal conjugate ... previous version used prior to 2010, the 7-valent pneumococcal ... published today in Vaccine. The U.S. Food ... 2010 after a series of trials. These trials found ... pneumococcal types than the previously used PCV7, did not ...
Breaking Medicine Technology:Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc. 2First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 2First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 3First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 4Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 2Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 3Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 4
... for New Combination, PARSIPPANY, N.J., May 21, ... amlodipine besylate with the angiotensin,receptor blocker olmesartan ... and diastolic blood pressure in,patients with hypertension, ... of Hypertension's Twenty-Second Annual Scientific,Meeting and Exposition ...
... Company (NYSE: BMY) today announced new data ... Baraclude (entecavir),demonstrated greater viral load reduction than ... was also seen at weeks 12 (primary ... randomized viral kinetics study,of 69 antiviral-naive chronic ...
Cached Medicine Technology:Amlodipine and Olmesartan Study Results Released; Late Breaker,Presented at American Society of Hypertension Twenty-Second Annual,Scientific Meeting (ASH 2007) 2Amlodipine and Olmesartan Study Results Released; Late Breaker,Presented at American Society of Hypertension Twenty-Second Annual,Scientific Meeting (ASH 2007) 3Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 2Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 3Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 4Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 5Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 6
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: